T h e ne w e ngl a nd jou r na l o f m e dicine S ickle cell disease is characterized by the presence of sickle hemoglobin (HbS), chronic hemolysis, recurrent pain episodes (called sickle cell-related pain crises or vaso-occlusive crises), multiorgan dysfunction, and early death. Sickle cell-related pain crises are the primary cause of health care encounters in patients with sickle cell disease. 1 These crises result in a decrease in quality of life 2 and an increase in the risk of death. 3 Crises are thought to be caused by vascular occlusion in the microcirculation, increased inflammation, and alterations in nociception. 4 The prevention of crises could minimize or prevent tissue and organ damage and decrease the subsequent risk of death among patients with sickle cell disease.
Although polymerization of deoxygenated HbS is the primary event in the pathophysiology of sickle cell disease, 5 the pathogenesis of vasoocclusion is complex. Vaso-occlusion is caused by the adhesion of sickle erythrocytes and leukocytes to the endothelium, which results in vascular obstruction and tissue ischemia. 6 The degree of sickle erythrocyte adhesion correlates with vaso-occlusion and increased severity of disease. 7 Activated and adherent leukocytes are the likely drivers of vaso-occlusion in collecting venules, whereas sickle erythrocytes may contribute to the occlusion of smaller vessels. 8 In addition, platelets can bind to erythrocytes, monocytes, and neutrophils to form aggregates, 9 ,10 which contribute to abnormalities of blood flow in patients with sickle cell disease. 11 Although the adhesion of leukocytes to the endothelium during inflammation can involve multiple molecules, the process is initiated by P-selectin. 12 P-selectin is found in storage granules of resting endothelial cells and platelets and is rapidly transferred to the cell membrane on activation of the cell during processes such as inflammation. P-selectin that is expressed on the surface of the endothelium mediates abnormal rolling and static adhesion of sickle erythrocytes to the vessel surface in vitro. 13, 14 Translocation of endothelial P-selectin to the cell surface results in the prompt adhesion of sickle erythrocytes to vessels and the development of vascular occlusion in transgenic mice with sickle cell disease. 15 Furthermore, activated platelets bind to neutrophils to form aggregates in a P-selectin-dependent manner in mice and humans with sickle cell disease. 16 Transgenic mice with sickle cell disease that are deficient in P-selectin and E-selectin have defective leukocyte recruitment to the vessel wall and are protected from vaso-occlusion. 17 In addition, the adherence of sickle erythrocytes and leukocytes to the endothelium is substantially reduced when P-selectin is blocked in transgenic mice expressing human HbS. 15, 18 Furthermore, doses of heparin that are sufficient to block P-selectin increase microvascular blood flow in patients with sickle cell disease. 19 These data support the concept that blockade of P-selectin could reduce the risk of vaso-occlusion, inflammation, and sickle cell-related pain crises.
Crizanlizumab is a humanized monoclonal antibody that binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Here we report the results of SUSTAIN (Phase 2, Multicenter, Randomized, PlaceboControlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of Crizanlizumab (SelG1) with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle CellRelated Pain Crises), a multicenter, randomized, double-blind, placebo-controlled, phase 2 trial to assess the safety and efficacy of crizanlizumab, with or without hydroxyurea therapy, in patients with sickle cell disease. The primary goal of the trial was to determine the effect of crizanlizumab therapy on the rate of sickle cellrelated crises during 52 weeks of treatment. 16 to 65 years of age and who had had 2 to 10 sickle cell-related pain crises in the 12 months before enrollment in the trial were eligible. Patients who were receiving hydroxyurea therapy were required to have been receiving the drug for at least 6 months, including taking a stable dose for at least the most recent 3 months, and they were not allowed to have any dose alteration during the 52-week treatment phase of the study, except for safety reasons. If patients were not receiving hydroxyurea, it could not be initiated. Patients who were undergoing long-term A Quick Take is available at NEJM.org
Me thods

Patients
Prevention of Pain Crises in Sickle Cell Disease red-cell transfusion therapy were excluded. The full list of eligibility criteria is provided in the Supplementary Appendix, available with the full text of this article at NEJM.org. All the patients provided written informed consent before enrolling in the trial.
Trial Design
The trial consisted of a 30-day screening phase, a 52-week treatment phase, and a 6-week followup evaluation phase. Randomization was performed centrally on the basis of a block design, with stratification according to the number of crises in the preceding year (2 to 4 or 5 to 10) and concomitant hydroxyurea use (yes or no).
Patients were assigned, in a 1:1:1 ratio, by an interactive Web-or voice-response system to receive low-dose crizanlizumab (2.5 mg per kilogram of body weight), high-dose crizanlizumab (5.0 mg per kilogram), or placebo. The participants, care providers, and those assessing outcomes were unaware of the group assignments.
Patients received two doses of crizanlizumab or placebo 2 weeks apart (loading doses) and then received a dose every 4 weeks (maintenance dosing) through week 50 for a total of 14 doses administered. Each dose was administered intravenously over a period of 30 minutes. During the treatment phase, the efficacy, safety, and pharmacokinetic and pharmacodynamic assessments were completed for each patient on the day of receipt of the initial dose, 2 weeks later, every 4 weeks through week 50, and at week 52, for a total of 15 visits. For the follow-up evaluation phase, patients returned for an assessment 6 weeks after the end of the treatment phase (8 weeks after receipt of the last dose) (see the protocol, available at NEJM.org).
Clinical Efficacy
The primary efficacy end point was the annual rate of sickle cell-related pain crises, which was calculated as follows: total number of crises × 365 ÷ (end date − date of randomization + 1), with the end date defined as the date of the last dose plus 14 days. Annualized rates were used for the comparisons because they take into account the duration that a participant was in the trial.
Sickle cell-related pain crises were defined as acute episodes of pain, with no medically determined cause other than a vaso-occlusive event, that resulted in a medical facility visit and treatment with oral or parenteral narcotic agents or with a parenteral nonsteroidal antiinflammatory drug. The acute chest syndrome, hepatic sequestration, splenic sequestration, and priapism were also considered to be crisis events. All the crises that were identified by trial investigators were adjudicated in a blinded fashion by an independent crisis-review committee.
Secondary efficacy assessments included the annual rate of days hospitalized, the times to first and second crises, the annual rate of uncomplicated crises (defined as crises other than the acute chest syndrome, hepatic sequestration, splenic sequestration, or priapism), the annual rate of the acute chest syndrome, and the Brief Pain Inventory questionnaire (Long-Form with 1-Week Recall; see the protocol). All the efficacy analyses were performed on the data collected during the 52-week treatment phase. Serum concentrations of crizanlizumab (pharmacokinetics) and the percent inhibition of P-selectin binding to PSGL-1 (pharmacodynamics) were assessed before dosing at baseline and at subsequent trial visits.
Safety
Safety assessments were performed during the screening phase, before and after the administration of crizanlizumab or placebo during the treatment phase, and during the follow-up evaluation phase. Safety assessments included physical examination, vital signs (blood pressure, pulse rate, respiratory rate, oxygen saturation, and oral body temperature), clinical laboratory tests (chemistry panel, complete blood count with reticulocyte count, urinalysis, prothrombin time and international normalized ratio, activated partial-thromboplastin time, and pregnancy tests), 12-lead electrocardiogram, and assessment of immunogenicity. Reported adverse events were coded with the use of preferred terms from the Medical Dictionary for Regulatory Activities, version 16.1. An independent data and safety monitoring committee reviewed safety during the trial.
Trial Oversight
The academic authors and the authors who are employees of the sponsor (Selexys Pharmaceuticals) were jointly responsible for the trial design. The first author, the authors who are employees of the sponsor, and a clinical research organization (Quintiles, paid by the sponsor) prepared the trial protocol. Data were collected, maintained, and analyzed by the Quintiles Biostatistics division. The first draft of the manuscript was prepared by the first author, with substantial review and comments by the other authors. The first author, in consultation with the other authors, made the decision to submit the manuscript for publication. All the authors had access to the data and signed confidentiality agreements with the sponsor regarding the data. The authors take responsibility for the veracity and completeness of the data reported and for adherence to the trial protocol. No one who is not an author contributed to the manuscript.
Statistical Analysis
We calculated that a sample of at least 50 patients per group would provide the trial with a statistical power of greater than 90%, at an alpha level of 0.05, to detect a 40% lower annual rate of crises with crizanlizumab than with placebo, with the use of a stratified Wilcoxon rank-sum test, assuming a median rate of crises per year in the placebo group of 3.0 with a predicted standard deviation of 1.7. For the primary end point, the analysis included all 198 patients who underwent randomization, according to the intention-to-treat principle.
The crisis rate for every patient was annualized to 12 months. The annual crisis rate was imputed for patients who did not complete the trial. The difference in the annual crisis rate between the high-dose crizanlizumab group and the placebo group was analyzed with the use of the stratified Wilcoxon rank-sum test, with the use of categorized history of crises in the previous year (2 to 4 or 5 to 10 crises) and concomitant hydroxyurea use (yes or no) as strata. A hierarchical testing procedure was used (alpha level of 0.05 for high-dose crizanlizumab vs. placebo, and if significant, low-dose crizanlizumab vs. placebo).
The annual crisis rates in the per-protocol population (i.e., all the patients who underwent randomization, received at least 12 of the 14 planned doses of crizanlizumab or placebo, and had no major protocol violations that would affect the efficacy assessments), the crisis rates in all subgroups, the rates of uncomplicated crises and the acute chest syndrome, and the annual rates of days hospitalized were analyzed with the use of the same method as that for the primary end point. The log-rank test was used to compare the times to the first and second crises. The change from baseline in responses on the Brief Pain Inventory questionnaire was analyzed with the use of a mixed linear model with repeated measures.
R esult s
Patients
From August 2013 through January 2015, a total of 198 patients at 60 sites in the United States (151 patients), Brazil (40), and Jamaica (7) met the eligibility criteria and were randomly assigned to receive high-dose crizanlizumab (67 patients), low-dose crizanlizumab (66), or placebo (65) (Fig. S1 in the Supplementary Appendix). Of the patients who underwent randomization, 129 completed the trial. The numbers of patients who discontinued early from the trial were balanced among the three groups (24 patients in the highdose crizanlizumab group, 21 in the low-dose crizanlizumab group, and 24 in the placebo group). The characteristics and baseline values of the patients in the three groups were generally similar (Table 1 ). An expanded list of characteristics and baseline values is provided in Table S1 in the Supplementary Appendix.
Clinical Efficacy
Primary End Point
At the end of the treatment phase, the median crisis rate per year in the intention-to-treat population was 1.63 in the high-dose crizanlizumab group, as compared with 2.98 in the placebo group (indicating a 45.3% lower rate with high-dose crizanlizumab, P = 0.01) ( Table 2 ). The median crisis rate per year in the low-dose crizanlizumab group was 2.01 (indicating a 32.6% lower rate than in the placebo group, P = 0.18). A total of 24 of 67 patients (36%) in the highdose crizanlizumab group, 12 of 66 (18%) in the low-dose crizanlizumab group, and 11 of 65 (17%) in the placebo group had a crisis rate of zero during the treatment phase.
The primary end-point findings were supported by a sensitivity analysis of the annual crisis rate among the 125 patients in the per-protocol population. The median crisis rate per year in the per-protocol population was 1.04 in the highdose crizanlizumab group, as compared with 2.18 in the placebo group (indicating a 52.3%
Prevention of Pain Crises in Sickle Cell Disease lower rate with high-dose crizanlizumab, P = 0.02). The median crisis rate per year in the low-dose crizanlizumab group was 2.00 (indicating a 8.3% lower rate than in the placebo group, P = 0.13). The number of patients who had a crisis rate of zero was 15 of 40 patients (38%) in the high-dose crizanlizumab group, 7 of 44 (16%) in the low-dose crizanlizumab group, and 5 of 41 (12%) in the placebo group.
Analyses of the annual rates of sickle cellrelated pain crises in the intention-to-treat population were performed in subgroups defined according to concomitant hydroxyurea use, categorized history of crisis frequency, and sickle cell disease genotype. The median crisis rate per year among patients receiving concomitant hydroxyurea therapy was 2.43 in the high-dose crizanlizumab group, as compared with 3.58 in the placebo group (indicating a 32.1% lower rate with high-dose crizanlizumab). The median crisis rate per year among patients who were not receiving concomitant hydroxyurea therapy was 1.00 in the high-dose crizanlizumab group, as compared with 2.00 in the placebo group (indicating a 50.0% lower rate with high-dose crizanlizumab).
The median crisis rate per year among patients who had had 2 to 4 crises in the previous 12 months was 1.14 in the high-dose crizanlizumab group, as compared with 2.00 in the placebo group (indicating a 43.0% lower rate with highdose crizanlizumab). The median crisis rate per year among patients who had had 5 to 10 crises in the previous 12 months was 1.97 in the highdose crizanlizumab group, as compared with 5.32 in the placebo group (indicating a 63.0% lower rate with high-dose crizanlizumab). * The high-dose crizanlizumab group received 5.0 mg of crizanlizumab per kilogram of body weight, and the low-dose crizanlizumab group 2.5 mg per kilogram. There were no significant between-group differences in the characteristics listed here. HbSS denotes homozygous hemoglobin S. † Race was self-reported. ‡ Other sickle cell disease genotypes included sickle hemoglobin C disease (HbSC), sickle β 0 -thalassemia (HbSβ 0 -thalassemia), sickle β + -thalassemia (HbSβ + -thalassemia), and others. Difference from placebo -% −50.5 0.0 -* The primary end point was the annual rate of crises in the high-dose crizanlizumab group versus the placebo group. The intention-to-treat population included all patients who underwent randomization. The per-protocol population included all the patients who underwent randomization, received at least 12 of the 14 planned doses of crizanlizumab or placebo, and had no major protocol violations that would affect the efficacy assessments. P values are for the comparison between the active-treatment group and placebo and were calculated with the use of a stratified Wilcoxon rank-sum test. IQR denotes interquartile range. The median crisis rate per year among patients with the HbSS genotype was 1.97 in the high-dose crizanlizumab group, as compared with 3.01 in the placebo group (indicating a 34.6% lower rate with high-dose crizanlizumab). The median crisis rate per year among patients with genotypes other than HbSS (i.e., those with HbSC, HbSβ 0 -thalassemia, HbSβ + -thalassemia, and other genotypes) was 0.99 in the high-dose crizanlizumab group, as compared with 2.00 in the placebo group (indicating a 50.5% lower rate with high-dose crizanlizumab).
Secondary End Points
The median rate of days hospitalized was 4.00 per year in the high-dose crizanlizumab group and 6.87 per year in the placebo group. This rate was 41.8% lower with high-dose crizanlizumab than with placebo, although the difference was not significant (P = 0.45) ( Table 3) .
The median time to the first crisis was significantly longer among patients receiving highdose crizanlizumab than among those receiving placebo (4.07 vs. 1.38 months, P = 0.001), as was the median time to the second crisis (10.32 vs. 5.09 months, P = 0.02) ( Table 3 ). The lower crisis frequency with high-dose crizanlizumab was evident within 2 weeks after the start of the 52-week treatment phase and was maintained throughout this phase (Fig. 1A) . The median times to the first and second crises among patients receiving low-dose crizanlizumab did not differ significantly from the times among patients receiving placebo (Fig. 1A and 1B and Table 3 ). † P values are for the comparison between the active-treatment group and the placebo group and were calculated with the use of a stratified Wilcoxon rank-sum test. ‡ The 75% value for the interquartile range was not observed within the 52-week trial and was considered to be not reportable (NR). § P values are for the comparison between the active-treatment group and the placebo group during the treatment phase and were calculated with the use of the log-rank test. 
The rate of uncomplicated crises per year was 62.9% lower in the high-dose crizanlizumab group than in the placebo group (median rate, 1.08 vs. 2.91; P = 0.02). In this trial, the acute chest syndrome, hepatic sequestration, splenic sequestration, and priapism were rare (median rate, 0.00 in all groups), and there were no significant differences between either of the activetreatment groups and the placebo group. Assessment of quality of life was performed with the Brief Pain Inventory questionnaire. Changes in the pain-severity domain and the pain-interference domain of the Brief Pain Inventory over the course of the trial tended to be small. There were no significant changes from baseline in the least-squares means during the trial.
Measures of Hemolysis
To investigate whether crizanlizumab had an effect on hemolytic variables in patients with sickle cell disease, changes in hemoglobin, lactate dehydrogenase, number of reticulocytes, haptoglobin, and indirect bilirubin were assessed during the study. No significant differences were observed in any of these variables between patients receiving crizanlizumab and those receiving placebo (data not shown).
Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Crizanlizumab
The serum concentrations of crizanlizumab reached steady-state levels after the loading doses, were maintained throughout the 52-week treatment period, and were dose-proportional (Fig. S2A in the Supplementary Appendix) . The mean trough concentrations of crizanlizumab during the maintenance phase (weeks 6 to 50) ranged from 2.8 to 6.8 μg per milliliter with low-dose crizanlizumab and from 10.5 to 15.0 μg per milliliter with high-dose crizanlizumab. Highdose crizanlizumab effectively blocked P-selectin binding to PSGL-1 throughout the treatment phase, whereas low-dose crizanlizumab was associated with only partial blockade (Fig. S2B in the Supplementary Appendix). Antibodies against crizanlizumab were not detected.
Safety
Serious adverse events were reported in 55 patients, including 17 patients in the high-dose crizanlizumab group, 21 in the low-dose crizanlizumab group, and 17 in the placebo group (Table 4) . The serious adverse events that occurred in at least 2 patients in either activetreatment group and at a higher frequency than in the placebo group were pyrexia and influenza. A total of 5 patients died during the trial, including 2 patients in the high-dose crizanlizumab group (1 patient from the acute chest syndrome, and 1 from endocarditis and sepsis), 1 in the low- Prevention of Pain Crises in Sickle Cell Disease dose crizanlizumab group (from the acute chest syndrome, aspiration, respiratory failure, and progressive vascular congestion), and 2 in the placebo group (1 from right ventricular failure, and 1 from vaso-occlusive crisis, ischemic stroke, coma, sepsis, and venous thrombosis of the right lower limb). Three additional single-occurrence adverse events that were considered to be both serious and life-threatening but that did not result in death included sepsis (in the placebo group), anemia (in the low-dose crizanlizumab group), and intracranial hemorrhage (in the low-dose crizanlizumab group). The patient with intracranial hemorrhage was being treated with ketorolac, which is associated with an increased risk of hemorrhagic stroke, 20, 21 at the time of the event. No other clinically significant bleeding events were observed in the trial. Adverse events that occurred in 10% or more of the patients in either active-treatment group were headache, back pain, nausea, arthralgia, pain in upper and lower limbs, urinary tract infection, upper respiratory tract infection, pyrexia, diarrhea, musculoskeletal pain, pruritus, vomiting, and chest pain. 
Chest pain 1 (2) 7 (11) 1 (2) * Adverse events were coded with the use of preferred terms from the Medical Dictionary for Regulatory Activities. The safety population included patients who underwent randomization and received at least one dose of crizanlizumab or placebo. † The most frequent serious adverse events were those that occurred in at least two patients in either active-treatment group. ‡ The most frequent adverse events were those that occurred in at least 10% of the patients in either active-treatment group. T h e ne w e ngl a nd jou r na l o f m e dicine
Discussion
Despite an increased understanding of the pathophysiology of sickle cell disease, the treatment options for disease-related complications, including sickle cell-related pain crises, remain limited. Hydroxyurea, which was approved by the Food and Drug Administration in 1998, is the only drug that has been shown to modify the natural history of sickle cell disease. 22 However, many patients who receive hydroxyurea therapy continue to have crises, end-organ damage, and a decreased life expectancy. 23 In addition, adherence to the hydroxyurea regimen remains a challenge. 24 Trials of new drugs for the prevention of crises have not shown significant or clinically meaningful results. 25, 26 In this randomized, phase 2 trial, we observed that treatment with high-dose crizanlizumab resulted in an annual rate of sickle cellrelated pain crises that was 45.3% lower than the rate with placebo. In addition, the median times to the first and second crises were two to three times as long in patients receiving highdose crizanlizumab as in those receiving placebo. These treatment effects were significant.
In this trial, we enrolled patients who were receiving concomitant hydroxyurea as well as those who were not receiving hydroxyurea. The annual crisis rate was 32.1% lower with high-dose crizanlizumab than with placebo among patients receiving hydroxyurea and 50.0% lower among patients who were not receiving hydroxyurea.
Patients with all the common sickle cell disease genotypes were enrolled in this trial. Genotypes other than HbSS were observed in 29% of the patients who underwent randomization. The annual crisis rate was 34.6% lower with high-dose crizanlizumab than with placebo among patients with the HbSS genotype and 50.5% lower among those with a genotype other than HbSS.
No significant differences were observed in markers of hemolysis (hemoglobin, lactate dehydrogenase, haptoglobin levels, number of reticulocytes, and indirect bilirubin) between patients receiving crizanlizumab and those receiving placebo (data not shown). This finding suggests that the observed clinical benefit derived from P-selectin inhibition did not involve a reduction in hemolysis.
The overall incidences of adverse events and serious adverse events among the patients treated with crizanlizumab were similar to the incidences among patients who received placebo. A detectable antibody response against crizanlizumab did not develop in any patient during the trial. Longer follow-up and monitoring are necessary to ensure that late neutralizing antibodies do not emerge that might limit the ability to administer crizanlizumab on a long-term basis.
In conclusion, the P-selectin inhibitor crizanlizumab was associated with a significantly lower frequency of sickle cell-related pain crises than placebo among patients with sickle cell disease, and crizanlizumab appeared to be associated with a low rate of adverse effects. Clinically meaningful lower rates of crises were observed with highdose crizanlizumab than with placebo, regardless of concomitant hydroxyurea use or sickle cell disease genotype.
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